Researchers have developed an AI-based wearable device, called Revoice, to help individuals communicate effectively after a stroke. The system, worn around the neck, uses sensors to capture carotid pulse signals and subtle vibrations from throat muscles to reconstruct intended words and sentences in real time, potentially transforming the lives of stroke patients living with dysarthria.
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The analysis of this special form of tau has revealed a relationship between high levels of the protein and extensive brain injury, a higher risk of complications, and poorer outcomes.
Affluent Medical SAS is becoming Carvolix after it entered into binding agreements to acquire Caranx Medical SAS for €16.6 million (US$19.34 million) and Artedrone SAS for €11.4 million. The aim is to create an integrated med tech company which will focus on revolutionizing cardiac valve replacement and stroke treatment through AI-driven autonomous mini-robots and innovative implants.
Inhibiting transient receptor potential melastatin 2 (TRPM2) may mitigate injury arising from ischemic stroke. Researchers at Zhejiang University and its medical school previously reported a small-molecule inhibitor of TRPM2, which also inhibited the human ether-a-go-go-related gene (hERG) channel, implying high risk of cardiotoxicity.
Simcere Pharmaceutical Co. Ltd. has described stachybotrys microspore triprenyl phenols (SMTPs) acting as plasminogen activators reported to be useful for the treatment of thromboembolism.
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images.
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images.
Taho Pharmaceuticals Ltd. announced an NDA submission to the U.S. FDA for TAH-3311, developed as the world’s first oral dissolving film formulation of apixaban, marking a regulatory milestone for the Taipei-based biotech.
Taho Pharmaceuticals Ltd. announced an NDA submission to the U.S. FDA for TAH-3311, developed as the world’s first oral dissolving film formulation of apixaban, marking a regulatory milestone for the Taipei-based biotech.
Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in ischemic stroke pathology by mediating necroptosis and promoting neuroinflammation, both of which contribute to secondary brain injury and worsen clinical outcomes.
